IndraLab

Statements

FADH2 inhibits JAK1. 2 / 2

| 2

➶

reach

"Ruxolitinib is an FDA approved targeting JAK1 and JAK2 inhibitor."

| PMC

➶

reach

"Ruxolitinib is an FDA approved drug for the treatment of myelofibrosis and specifically inhibits Jak1 and Jak2."

27738655

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

FADH2 inhibits JAK1. 2 / 2

INDRA sources:

Databases

Reading